A Phase 2 interventional study of Lactobacillus Plantarum 299v and Crystalline cellulose powder in Depression and Anxiety Disorder, sponsored by Medical University of Bialystok. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-07.
Sponsored by Medical University of Bialystok · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Depression with a site in Poland — 19 open to participants now, 23 under way, 8 of them phase 3. Depression · Poland.
Among the 95 studies in Depression with a site in Poland, this one is the 62nd largest by enrollment of the 81 interventional ones that give a count, is one of 2 that started in 2014, is one of 14 in phase 2, and was the 27th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →19 of the 95 studies in Depression with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Draig Therapeutics Ltd · Sites in Poland, United States, Bulgaria and 2 more countries
Ages 18–75
Aziende Chimiche Riunite Angelini Francesco S.p.A · Sites in Poland
Ages 55+
Cybin IRL Limited · Sites in Poland, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 15 · Phase 3 33 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 200 across the 81 interventional studies, 391 across the 14 observational. Of the 65 that completed or were terminated, 22 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 95 have an industry lead sponsor. The 10 most frequent:
Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.
Medical University of Bialystok has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
11 of the studies in Depression with a site in Poland that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT06786624Phase 3Neurocrine BiosciencesStudy to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT07377682Aziende Chimiche Riunite Angelini Francesco S.p.AReal-world Clinical Response to Trazodone in Italy, Poland, and Romania | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 95 studies in Depression with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to determine the influence of supplementation of probiotic Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with SSRI (Selective Serotonin Reuptake Inhibitor) in patients with major depression.
For period of 8 weeks patient will receive probiotic Lactobacillus Plantarum 299V or its placebo as a supplementation of regular depression treatment with SSRI (Escitalopram or Sertraline). Psychometric and biochemical parameters will be monitored and evaluated. At day one, after 3 weeks (day 21) and after 8 weeks (day 56) of the study psychometric parameters will be measured such as Hamilton Depression Rating Scale, PSS-10 Scale, SCL-90 scale. At day one and after 8 weeks (day 56) of the study cognitive functions will be measured using: CVLT- California Verbal Learning Test, RFFT Ruff Figural Fluency Test, Stroop Test, Connecting Points Test (A and B), Attention and Perceptivity Test. At day one and after 8 weeks (day 56) of the study biochemical parameters will be measured such as: morning cortisol, pro and anti-inflammatory cytokines, tryptophan and its kynurenic pathway metabolites concentrations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
Drug: Lactobacillus Plantarum 299v · Drug: Escitalopram · Drug: Sertraline
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
Drug: Crystalline cellulose powder · Drug: Escitalopram · Drug: Sertraline
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
5-20mg daily
50-100mg daily
Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.
Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study
Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.
Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study
Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.
Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study
Cognitive functions evaluation - California Verbal Learning Test (CVLT)
Time frame: At day one, after 8 weeks (day 56) of the study
Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT)
Time frame: At day one, after 8 weeks (day 56) of the study
Cognitive functions evaluation - Stroop Test (A and B)
Time frame: At day one, after 8 weeks (day 56) of the study
Cognitive functions evaluation - Connecting Points Test (A and B)
Time frame: At day one, after 8 weeks (day 56) of the study
Cognitive functions evaluation - Attention and Perceptivity Test
Time frame: At day one, after 8 weeks (day 56) of the study
Biochemical analysis - morning cortisol level
Biochemical analysis will be based on pro-inflammatory and anti-inflammatory cytokines measurements, morning cortisol concentration, tryptophan and its kynurenic pathway metabolites measurements.
Time frame: At day one, after 8 weeks (day 56) of the study
Biochemical analysis - cytokines measurements profile
Time frame: At day one, after 8 weeks (day 56) of the study
Biochemical analysis - kynurenic pathway metabolites measurements profile
Time frame: At day one, after 8 weeks (day 56) of the study
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jun 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactiplantibacillus plantarum 299V
Medical University of Bialystok